Novocure Ltd
NASDAQ:NVCR

Watchlist Manager
Novocure Ltd Logo
Novocure Ltd
NASDAQ:NVCR
Watchlist
Price: 30.97 USD 1.57% Market Closed
Market Cap: 3.4B USD
Have any thoughts about
Novocure Ltd?
Write Note

Gross Margin
Novocure Ltd

76.4%
Current
77%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
76.4%
=
Gross Profit
441.5m
/
Revenue
577.7m

Gross Margin Across Competitors

Country JE
Market Cap 3.3B USD
Gross Margin
76%
Country US
Market Cap 199B USD
Gross Margin
56%
Country US
Market Cap 191.3B USD
Gross Margin
67%
Country US
Market Cap 141.3B USD
Gross Margin
64%
Country US
Market Cap 134.2B USD
Gross Margin
69%
Country IE
Market Cap 104.6B USD
Gross Margin
65%
Country US
Market Cap 65.6B USD
Gross Margin
45%
Country DE
Market Cap 58.1B EUR
Gross Margin
38%
Country US
Market Cap 44.5B USD
Gross Margin
79%
Country CN
Market Cap 307.8B CNY
Gross Margin
64%
Country US
Market Cap 36.3B USD
Gross Margin
41%
No Stocks Found

Novocure Ltd
Glance View

Market Cap
3.3B USD
Industry
Health Care

Novocure Ltd. operates in the intriguing intersection of medical innovation and patient-centric care, focusing on harnessing electric fields to treat cancerous tumors, a modality known as Tumor Treating Fields (TTFields). Founded in 2000 and based in the Isle of Jersey, the company has pioneered an unconventional approach that challenges traditional cancer treatments like chemotherapy and radiation. By deploying low-intensity, alternating electric fields through adhesive patches on the patient's body, TTFields interfere with the division of cancer cells, inhibiting tumor growth without the typical debilitating side effects. Novocure’s proprietary technology offers a unique, non-invasive treatment option primarily targeting aggressive cancers, such as glioblastoma and non-small cell lung cancer, positioning it as a notable innovator in the oncology space. The company's business model thrives on a blend of therapy innovation and strategic partnerships. Novocure generates revenue through sales of its wearable medical device, which continually delivers TTFields therapy. These sales are supplemented by the securing of insurance reimbursements, which is crucial for patient access and company profitability. By conducting numerous clinical trials, Novocure not only aims to expand the applicability of TTFields to other forms of cancer but also reinforces its value proposition to the healthcare community. Strategic collaborations with researchers and leading cancer centers further enhance its market penetration. As the company continues to invest in research and expand its treatment portfolio, its commitment to transforming cancer therapy by offering a new dimension of hope remains at the forefront of its mission.

NVCR Intrinsic Value
25.58 USD
Overvaluation 17%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
76.4%
=
Gross Profit
441.5m
/
Revenue
577.7m
What is the Gross Margin of Novocure Ltd?

Based on Novocure Ltd's most recent financial statements, the company has Gross Margin of 76.4%.